AQXP News Alert Aquinox Pharmaceuticals Inc. (AQXP) 10.29 02/14/2015

Aquinox Pharmaceuticals Inc. (AQXP) 10.29 $AQXP

Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 FLAGSHIP Trial of AQX-1125 in Chronic Obstructive Pulmonary Disease Exacerbations
GlobeNewswire - Mon Feb 02, 9:05AM CST
Aquinox Pharmaceuticals, Inc. ("Aquinox" (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that it has reached its target enrollment in the Phase 2 FLAGSHIP trial of AQX-1125 for the treatment of chronic obstructive pulmonary disease (COPD) following a recent exacerbation.
AQXP: 10.29 (-0.54)

Aquinox Pharma completes enrollment in Phase 2 for lead product candidate
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 9:04AM CST

AQXP: 10.29 (-0.54)

Aquinox Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Thu Jan 29, 9:03AM CST
Aquinox Pharmaceuticals, Inc. ("Aquinox" (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox's President & CEO, will present a corporate overview at two upcoming investor conferences.
AQXP: 10.29 (-0.54)

Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 11:45AM CST

BEBE: 3.90 (+0.01), PCYC: 163.28 (+0.23), NLST: 1.86 (unch), AQXP: 10.29 (-0.54), ASPS: 22.32 (+0.09), OCN: 9.10 (+0.09), PHMD: 1.68 (+0.04), AAMC: 173.53 (-8.22), MOMO: 11.02 (-0.47), WBAI: 17.36 (-0.30), ELX: 6.57 (+0.22), TLYS: 13.08 (-0.19), SGNL: 3.91 (+2.15), SFY: 2.91 (+0.26), CLRX: 1.84 (+0.04), ECOM: 9.69 (+0.63), LOAN: 3.63 (-0.09), GURE: 1.64 (-0.04), KBH: 14.39 (+0.26), HLSS: 16.15 (-0.14)

Aquinox Starts Dosing for an Atopic Dermatitis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 4:20PM CST
Aquinox (AQXP) has started dosing in the phase II KINSHIP study on its atopic dermatitis candidate, AQX-1125.
AQXP: 10.29 (-0.54), ANAC: 40.76 (-0.07), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)

Daily Pharma Dose: New Research on Hospira, Aquinox, Sucampo, NephroGenex and OncoGenex
PR Newswire - Wed Dec 31, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Hospira (NYSE: HSP), Aquinox (NASDAQ: AQXP), Sucampo (NASDAQ: SCMP), NephroGenex (NASDAQ: NRX), and OncoGenex (NASDAQ: OGXI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AQXP: 10.29 (-0.54), OGXI: 2.06 (-0.05), NRX: 6.67 (-0.14), SCMP: 15.32 (+0.04), HSP: 87.35 (unch)

Aquinox Pharma starts Phase 2 development of dermatitis med
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 3:28PM CST

AQXP: 10.29 (-0.54)

Aquinox Pharmaceuticals Initiates Patient Dosing in the Phase 2 Clinical Trial of AQX-1125 in Atopic Dermatitis
GlobeNewswire - Tue Dec 30, 3:05PM CST
Aquinox Pharmaceuticals, Inc. ("Aquinox" (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that it has initiated dosing in a Phase 2 clinical trial of AQX-1125 for the treatment of atopic dermatitis (AD).
AQXP: 10.29 (-0.54)

Aquinox Pharmaceuticals elects David C. Mitchell as VP of its Global Regulatory Affairs & Quality Assurance
M2 - Wed Dec 10, 6:32AM CST
Pharmaceutical company Aquinox Pharmaceuticals (NasdaqGM:AQXP) disclosed on Tuesday the election of David C. Mitchell as vice president of its Global Regulatory Affairs & Quality Assurance.
AQXP: 10.29 (-0.54)

Aquinox Pharmaceuticals Announces Appointment of Mr. David C. Mitchell as Vice President, Global Regulatory Affairs & Quality Assurance
GlobeNewswire - Tue Dec 09, 8:20AM CST
Aquinox Pharmaceuticals, Inc. ("Aquinox" (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, is pleased to announce the appointment of Mr. David C. Mitchell as Vice President of Global Regulatory Affairs & Quality Assurance. Mr. Mitchell will join Aquinox's management team to guide the strategic direction of Aquinox's global regulatory and quality assurance functions.
BIIB: 391.66 (-0.45), AQXP: 10.29 (-0.54), ABBV: 58.05 (+1.00)

Aquinox (AQXP) Enters Overbought Territory